

PRESS RELEASE November 8, 2006

Presentation of Interim Report

Invitation to press and analyst meeting and conference call

The biopharma company Biovitrum, listed on the Stockholm Stock Exchange since September 15, 2006, invites media and analysts to a press- and analyst meeting in Stockholm and conference call on Tuesday November 14 in conjunction with the disclosure of the interim report for January-September 2006. The report is scheduled for publication at 08:30 (CET) on the same date.

The report will be presented by CEO Mats Pettersson and CFO Göran Arvidson.

Press and analyst meeting in Stockholm

Time: Tuesday, November 14 at 10:30 (CET)
Venue: IVA, Grev Turegatan 16, Stockholm, conference room "Rausing"
Coffee will be served following the presentation

Please register not later than 16:00 (CET) on November 13, 2006 by either sending an email to lena.bjurfors@biovitrum.com or contacting Lena Bjurfors at +46 8 697 3092 or Marianne Gripe at +46 8 697 3427.

Conference Call

Time: Tuesday, November 14 at 15:00 (CET)
Dial-in: +46 8 506 269 30

A recorded version of the conference call will be available for seven days on phone No. +46 8 506 269 49, access code: 160600

The slide presentation from both the conferences will be available at <http://www.biovitrum.net/templates/InformationPage.aspx?id=404>

For more information, please contact:

Biovitrum AB (publ)

Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 2085
Mobile: +46 73 433 20 85
annakarin.kallen@biovitrum.com

Anders Martin-Löf, Director Investor Relations
Phone: +46 8 697 37 07
Mobile: +46 70 624 32 56
anders.martin-lof@biovitrum.com

About Biovitrum

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has approximately revenues of USD 119 million and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com/.